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ABSTRACT
Aim: The purpose of this study is to evaluate the cost-effectiveness of
oseltamivir for inﬂuenza in Japan considering the complications and the
emergence of oseltamivir-resistant virus.
Methods: Study design is a cost-effectiveness analysis in decision analytic
modeling based on previously published evidence. Outcome measures
included costs and quality-adjusted life year (QALY).
Results and Conclusion: In the base-case analysis, the incremental cost-
effectiveness ratio (ICER) of oseltamivir during inﬂuenza and complica-
tions was JPY398,571 ($3320) per QALY without productivity loss,
which implied oseltamivir is evidently cost-effective. Furthermore, con-
sidering the productivity loss, the ICER for oseltamivir turned to be
negative, which means simply dominant. When the prevalence was in the
low range of 10% to 38%, oseltamivir became less cost-effective than
conventional treatment. Regarding potential emergence of the drug-
resistant virus, we found the dominance of oseltamivir will vanish if the
emerging rate becomes larger than 27%. The two-way sensitivity analysis
also suggested that if the resistant virus rate becomes less and the preva-
lence higher, then oseltamivir becomes more advantageous. The analysis
for uncertainty, using cost-effectiveness acceptability curve by Monte
Carlo simulation, resulted in the estimate of about 80% chance that
oseltamivir could be cost-effective at the willingness-to-pay level of
JPY6,000,000 ($50,000), which is commonly accepted as an affordable
threshold.
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Introduction
Inﬂuenza is a common viral respiratory infection that typically
occurs in winter. Each year in Japan, a 5% to 10% fraction of
people gets infected with inﬂuenza, resulting in about 1000 to
2000 deaths by inﬂuenza and 5000 deaths due to complications
such as pneumonia. Most of the fatal cases are the elderly over 65
years old and patients with high risk. An about 20% to 25%
fraction of the elderly infected with inﬂuenza is estimated to
develop pneumonia, and 5% of those patients will be dead [1–3].
The annual incident rate of inﬂuenza in children is estimated to
be 1.5 to 3.0 times as high as that in adults [4].
It is demonstrated that the treatment with the neuraminidase
inhibitors such as oseltamivir and zanamivir reduced the dura-
tion of inﬂuenza symptoms in adult patients by 1 to 1.5 days
[5–8]. In addition, both drugs reduced the incidence of compli-
cations requiring for antibiotics [5,8–10]. In Japan, oseltamivir is
approved in patients: 1) symptomatic for no more than 2 days
and 2) diagnosed for inﬂuenza by the rapid test. The combination
of the rapid diagnostic test and a subsequent prescription of
oseltamivir costs JPY6250 ($52.00) [11] per primary dose per
patient. Then, the total national expenditure for oseltamivir in
Japan has become an economic burden since oseltamivir has been
prescribed for 35 million people these 5 years.
An etiological concern has been also raised about emerging of
drug-resistant virus (DRV) [12].
According to those concerns, the following questions were
raised in our study: 1) is oseltamivir cost-effective in the Japanese
setting, taking complications into account? and 2) with regard to
the emerging DRV, how does it affect the cost-effectiveness of
oseltamivir? The objective of our study is to address these ques-
tions, using a decision analytic modeling.
Method
Modeling and Assumptions
We modeled a decision tree (Fig. S1) comparing two strategies: 1)
with rapid diagnostic testing followed by treatment with oselta-
mivir, and 2) without testing followed by conventional treat-
ments without oseltamivir. The conventional treatments include
a dose of febrifuge such as acetaminophen. The probabilities
assigned to the decision tree are shown in Tables S1 and S2. In
Figure S1, emerging of the DRV is represented at a chance node
employing the efﬁcacy of oseltamivir for the DRV. Outcomes
were measured with the quality-adjusted life years (QALYs) and
the costs. The time horizon for the analysis was set in 53 days.
The prevalence of inﬂuenza, 60%, among the patients with
symptoms of inﬂuenza-like illness is shown in Table S1 [13,14].
The frequency of common secondary complications of inﬂuenza
is collected in the trials and other published data and shown in
Table S2 [1,10,15–18].
The costs assigned to the model are listed in Table S3
[11,19,20]. This analysis includes not only estimates of direct
medical costs but also of productivity loss due to inﬂuenza and
pneumonia.
To see Tables S1 and S2 and Figures S1 and S2, see Cost-
Effectiveness Analysis of Oseltamivir for Inﬂuenza Treatment
Considering the Virus Emerging Resistant to the Drug in Japan
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The productivity loss due to inﬂuenza was estimated with
JPY34,770 ($290.00) for oseltamivir and JPY39,638 ($330.00)
for conventional treatment by using the days needed to return to
normal activity, and by converting the estimated days into mon-
etary value based on the average gross Japanese income [21,22].
The productivity loss of hospitalization due to pneumonia was
also estimated with JPY91,808 ($765) for the elderly and
JPY180,804 ($1507) for adults under 64 years based on these
assumptions (see Cost-Effectiveness Analysis of Oseltamivir for
Inﬂuenza Treatment Considering the Virus Emerging Resistant to
the Drug in Japan Value in Health Supporting Information, Part
I at: http://www.ispor.org/Publications/value/ViHsupplementary/
ViH12s3_Nagase.asp).
Since the availability of utility data was limited in Japan, the
foreign literature [10,23] was employed to set the baseline values
in health-related quality of life due to inﬂuenza infection shown
in Table S4.
Figure S1 and Tables S1–S4 are shown in Cost-Effectiveness
Analysis of Oseltamivir for Inﬂuenza Treatment Considering
the Virus Emerging Resistant to the Drug in Japan Value in
Health Supporting Information, Part I at: http://www.ispor.org/
Publications/value/ViHsupplementary/ViH12s3_Nagase.asp.
Analysis
Please see Cost-Effectiveness Analysis of Oseltamivir for Inﬂu-
enza Treatment Considering the Virus Emerging Resistant to the
Drug in Japan Value in Health Supporting Information, Part II at:
http://www.ispor.org/Publications/value/ViHsupplementary/
ViH12s3_Nagase.asp.
Results
Base-case Analysis
Table S5 shows the main results in the form of cost-effectiveness
table. Without productivity loss, the total cost of oseltamivir per
one patient was estimated as JPY13,548 ($113), and JPY13,269
($111) for conventional treatment. Using the utilities data at
Table S4, the oseltamivir regimen earned 0.1381 QALYs and the
conventional treatment with 0.1374 QALYs. The incremental
cost-effectiveness ratio (ICER) of oseltamivir versus the conven-
tional treatment without productivity loss was estimated as
JPY398,571 ($3320) per QALY. On the other hand, considering
the productivity loss during the hospitalization due to pneumo-
nia, the ICER was changed to be negative, which means simple
dominance of oseltamivir over conventional therapy. Especially
for the elderly, the ICER for oseltamivir is simply dominant even
if the productivity loss was not included as shown in Table S6.
To see Tables S5 and S6, see Cost-Effectiveness Analysis of
Oseltamivir for Inﬂuenza Treatment Considering the Virus
Emerging Resistant to the Drug in Japan Value in Health
Supporting Information, Part II at: http://www.ispor.org/
Publications/value/ViHsupplementary/ViH12s3_Nagase.asp.
Sensitivity Analysis
Regarding the sensitivity analysis on prevalence of inﬂuenza,
the dominance of oseltamivir vanished when the prevalence
was under 39% for the case with productivity loss shown in
Figure S2a.
The result of sensitivity analysis on the rapid diagnostic test
showed that the dominance of oseltamivir vanishes when the
sensitivity of the test becomes fewer than 60%. Figure S2b shows
the result of two-way sensitivity analysis by prevalence of inﬂu-
enza and the sensitivity of the diagnostic test. That is, the treat-
ment with oseltamivir becomes dominant when the sensitivity of
the rapid test is higher than about 60% in the period of epidemics
(prevalence: more than 70%), and also when the sensitivity is
higher than 90% in the period of nonepidemics (prevalence: less
than 40%).
Regarding the emerging DRV, we examined how much the
effectiveness of oseltamivir would be reduced by the DRV. Then,
we found the dominance of oseltamivir vanishes if the emerging
rate of DRV is larger than 27% shown in Figure S3a. In the
two-way sensitivity analysis on prevalence and the emerging rate
of DRV, the emerging rate of the DRV had more inﬂuence in the
nonepidemic season rather than epidemic season. Therefore, if
we could get the less DRV rate and the higher prevalence of
inﬂuenza, oseltamivir would be the more advantageous. The
joint effect in detail is shown in Figure S3b.
The results of the probabilistic sensitivity analysis are shown
in Figure S4. Figure S4a illustrates the 95% conﬁdence eclipse
located at the North–East and South–East quadrants in a con-
densed form. In more details, a 57.86% portion at the North–
East quadrant and 20.24% at the South–East of the plotted pairs
were under the line with the slope of JPY6,000,000/QALY
($50,000/QALY), which is generally accepted as willingness-to-
pay (WTP) for medical technologies in Japan [24]. The similar
information as in Figure S4a, but in different shapes, is shown as
the cost-effectiveness acceptability curve in Figure S4b comparing
two curves for the oseltamivir to conventional treatment. At the
graph, a threshold of JPY6000,000/QALY on the horizontal
axis corresponds to about 80% probability of having better
cost-effectiveness.
To see Figures S2–4, see Cost-Effectiveness Analysis of
Oseltamivir for Inﬂuenza Treatment Considering the Virus
Emerging Resistant to the Drug in Japan Value in Health Sup-
porting Information: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH12s3_Nagase.asp).
Discussion
This study began with two questions about: 1) cost-effectiveness
of oseltamivir in the Japanese setting, considering the duration of
complications and 2) the degree of impact caused by the DRV on
the cost-effectiveness. The ﬁrst question was motivated by the
fact that, with quite a few studies from Japan reporting the crude
estimate of costs on oseltamivir, no cost-effectiveness analysis
was conducted, in any details, bringing into focus the complica-
tions after acute phase of the treatment. Hence, our decision tree
modeled three groups of children, adults, and the elderly, each of
which has possibilities leading to two categories of complica-
tions: pneumonia and the others. As a result, the ICER was
eventually estimated at JPY398,571/QALY ($3320/QALY),
costing without productivity loss, for the screening group fol-
lowed by oseltamivir therapy. This primary result of our study
suggests that, when considering the complications, it is very
cost-effective, compared to a threshold of $50,000/QALY com-
monly accepted to be cost-effective in medical technology assess-
ment [25]. It implies that oseltamivir may be useful in economic
terms in order to reduce a high proportion of hospitalization for
the elderly in Japan due to the complication of pneumonia.
The advantage of good cost-effectiveness in the oseltamivir
therapy becomes more evident when we consider the productiv-
ity loss in costing. The ICER in such a case turned to be negative,
which means that the strategy with oseltamivir is simply domi-
nant over the one without oseltamivir. Accordingly, oseltamivir is
recommended regardless of the perspectives in analysis, whether
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with productivity loss or without it, which represents the per-
spective of payers or society, respectively. Such a robustness of
the ICERs over the different perspectives, estimated in this study,
may justify the positive listing of oseltamivir in the Japanese
health insurance system of government since the system has a
universal coverage and premiums for all of the Japanese.
One of the concerns is uncertainty around the one-point
ICER estimate even if it is a good estimate. A problem-solving
approach for this concern is the probabilistic sensitivity analysis
shown in Figure S4. In this ﬁgure, the scattered plot and also the
cost-effectiveness acceptability curve seem to be in good shape,
suggesting that the oseltamivir group would be regarded as more
cost-effective at the chance of 78.1%, compared to the ratio of
JPY6,000,000/QALY ($50,000/QALY).
The recommendation for oseltamivir being favorable should
be carefully denied according to the results of sensitivity analyses.
The simplest rule of thumb is that the indication of oseltamivir is
not encouraged at the early or late stage of the epidemic when the
prevalence of inﬂuenza becomes lower than about 40% as illus-
trated from the one-way sensitivity analysis in Figure S2a. Also,
Figure S2b gives further information to physicians and public
health professionals how they could assess the change of oselta-
mivir’s dominance with respect to the interaction of two factors
such as the sensitivity of the rapid diagnostic test and the preva-
lence of the disease. To see Figure S2a and b, see Cost-
Effectiveness Analysis of Oseltamivir for Inﬂuenza Treatment
Considering the Virus Emerging Resistant to the Drug in Japan
Value in Health Supporting Information at: http://www.ispor.
org/Publications/value/ViHsupplementary/ViH12s3_Nagase.asp.
As the sensitivity of the test varies around 50% to 70%, taking
into account the worst value of 50%, then Figure S2b indicates
the prevalence must be maintained at least around 70% so that
the dominance of oseltamivir could be accomplished at the sat-
isfactory level. Based on this evidence, physicians should care-
fully identify the high-risk group with the prevalence of 70% or
higher before taking the rapid diagnostic test followed by the
oseltamivir therapy.
Regarding the second question, we obtained a threshold of
27% for the emerging rate of DRV, at which the expected values
of cost-effectiveness for two strategies cross over as shown in
Figure S3a. Figure S3b gives further information on the two-way
sensitivity analysis, as well as Figure S4b. It suggests that the
epidemiological evidence on the drug-resistance rate is crucially
important to assess how much the oseltamivir therapy can
provide us with cost-effectiveness beneﬁt under the circumstance
of changing prevalence in the epidemic period. It is a challenge
for physicians to control and suppress the rate of DRV around or
under 45% so that the beneﬁt of oseltamivir may not be lost even
at the peak stage of epidemic with the prevalence of 90% shown
at the bottom right of Figure S3b. As there is a concern about
high possibility that the wide spread of the drug-resistant H1N1
inﬂuenza virus might occur in Japan [26], our result would be
useful for public health decision-making when the DRV is spread
in the near future. To see Figures S3a and b and S4b, see Cost-
Effectiveness Analysis of Oseltamivir for Inﬂuenza Treatment
Considering the Virus Emerging Resistant to the Drug in Japan
Value in Health Supporting Information at: http://www.ispor.
org/Publications/value/ViHsupplementary/ViH12s3_Nagase.asp.
On the other hand, our analysis is subject to a number of
limitations, including scarce availability of Japanese evidence on
probabilities and utilities. Despite the effort ﬁnding relevant lit-
erature, the baseline probabilities for the analysis were employed
from a few articles such as the Japanese clinical trials and the
systematic reviews on the literature published in Western coun-
tries. Consequently, a selection bias of evidence might be inevi-
tably, to some extent, contained in the baseline analysis. The
utility assessment in our study is also limited with the same
reasons. To overcome the limitation with no utility values avail-
able for Japanese, we assumed unbiased transferability of evi-
dence from foreign countries to the Japanese setting. Such
limitations on data availability, of course, become a potential
threat to external validity of our study. Therefore, the validation
of our modeling based on the original data in Japan remains for
further investigations.
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